{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:08:20Z","timestamp":1788120500634,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03088-1","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T08:56:39Z","timestamp":1735376199000},"page":"1131-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparative Effectiveness of Fluticasone Furoate\/Umeclidinium\/Vilanterol and Budesonide\/Glycopyrrolate\/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3646-7828","authenticated-orcid":false,"given":"David","family":"Mannino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-9590","authenticated-orcid":false,"given":"Stephen","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-7673","authenticated-orcid":false,"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1316-9645","authenticated-orcid":false,"given":"Julien","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5118-1909","authenticated-orcid":false,"given":"Anabelle","family":"Tardif-Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Forero-Schwanhaeuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6296-8795","authenticated-orcid":false,"given":"Patrick","family":"Gravelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7564-5343","authenticated-orcid":false,"given":"Chris H.","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-5579","authenticated-orcid":false,"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7151-4311","authenticated-orcid":false,"given":"Rosirene","family":"Paczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"issue":"4","key":"3088_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/resp.14007","volume":"26","author":"P Lange","year":"2021","unstructured":"Lange P, Ahmed E, Lahmar ZM, Martinez FJ, Bourdin A. Natural history and mechanisms of COPD. Respirology. 2021;26(4):298\u2013321. https:\/\/doi.org\/10.1111\/resp.14007.","journal-title":"Respirology"},{"key":"3088_CR2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024. https:\/\/goldcopd.org\/2024-gold-report\/. Accessed April 29, 2024."},{"issue":"46","key":"3088_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.15585\/mmwr.mm7246a1","volume":"72","author":"Y Liu","year":"2023","unstructured":"Liu Y, Carlson SA, Watson KB, Xu F, Greenlund KJ. Trends in the prevalence of chronic obstructive pulmonary disease among adults aged \u226518 years\u2014United States, 2011\u20132021. MMWR Morb Mortal Wkly Rep. 2023;72(46):1250\u20136. https:\/\/doi.org\/10.15585\/mmwr.mm7246a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3088_CR4","unstructured":"Centers for Disease Control and Prevention. National Center for Health Statistics. National Health Interview Survey, 2019\u20132022. Analysis by the American Lung Assocation Research and Program Services Division using SPSS software. https:\/\/www.lung.org\/research\/trends-in-lung-disease\/copd-trends-brief\/data-tables\/trends-copd-race-ethnicity-sex-age. Accessed Sept 23, 2024."},{"key":"3088_CR5","unstructured":"Gillen EM, Mercado N, Sunkari K. Medicare enrollees with COPD compared to the general population. 2021. https:\/\/avalere.com\/insights\/medicare-enrollees-with-copd-compared-to-the-general-population. Accessed Sept 23, 2024."},{"key":"3088_CR6","unstructured":"Bilder S B-GZ, Jones B, Mohammadi I, Pulungan Z, Su Y, Teigland C, Vabson B. Who enrolls in Medicare Advantage vs. Medicare Fee-for-Service. Inovalon White Paper. 2023. https:\/\/www.inovalon.com\/wp-content\/uploads\/2023\/06\/Harvard-Inovalon-Medicare-Study.pdf. Accessed 15 Nov 2024."},{"issue":"5","key":"3088_CR7","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.chest.2023.11.040","volume":"165","author":"DM Mannino","year":"2024","unstructured":"Mannino DM, Roberts MH, Mapel DW, et al. National and local direct medical cost burden of COPD in the United States from 2016 to 2019 and projections through 2029. Chest. 2024;165(5):1093\u2013106. https:\/\/doi.org\/10.1016\/j.chest.2023.11.040.","journal-title":"Chest"},{"issue":"5","key":"3088_CR8","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jemermed.2020.07.001","volume":"59","author":"R Sorge","year":"2020","unstructured":"Sorge R, DeBlieux P. Acute exacerbations of chronic obstructive pulmonary disease: a primer for emergency physicians. J Emerg Med. 2020;59(5):643\u201359. https:\/\/doi.org\/10.1016\/j.jemermed.2020.07.001.","journal-title":"J Emerg Med"},{"issue":"18","key":"3088_CR9","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/nejmoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380. https:\/\/doi.org\/10.1056\/nejmoa1713901.","journal-title":"N Engl J Med"},{"key":"3088_CR10","unstructured":"GSK. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder). Prescribing information. 2023. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Trelegy_Ellipta\/pdf\/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF. Accessed 29 Apr 2024."},{"issue":"10","key":"3088_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358. https:\/\/doi.org\/10.1016\/s2213-2600(18)30327-8.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3088_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35\u201348. https:\/\/doi.org\/10.1056\/nejmoa1916046.","journal-title":"N Engl J Med"},{"key":"3088_CR13","unstructured":"AstraZeneca. BREZTRI AEROSPHERE (budesonide, glycopyrrolate, and formoterol fumarate). Prescribing information. 2022. http:\/\/www.azpicentral.com\/pi.html?product=breztri. Accessed 29 Apr 2024."},{"key":"3088_CR14","doi-asserted-by":"crossref","unstructured":"Noorduyn S, Young C, Lee L, et al. Adherence and persistence with fluticasone furoate\/umeclidinium\/vilanterol and budesonide\/glycopyrrolate\/formoterol fumarate among patients with chronic obstructive pulmonary disease: a real-world United States study. Presented at the American Thoracic Society 2024 International Conference; San Diego, CA, USA; May 17\u201322.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A3301"},{"issue":"3","key":"3088_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151357","volume":"11","author":"KJ Rothnie","year":"2016","unstructured":"Rothnie KJ, Mullerova H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS ONE. 2016;11(3): e0151357. https:\/\/doi.org\/10.1371\/journal.pone.0151357.","journal-title":"PLoS ONE"},{"key":"3088_CR16","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2147\/copd.s302241","volume":"16","author":"DW Mapel","year":"2021","unstructured":"Mapel DW, Roberts MH, Sama S, et al. Development and validation of a healthcare utilization-based algorithm to identify acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1687\u201398. https:\/\/doi.org\/10.2147\/copd.s302241.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"521","key":"3088_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390\u2013400. https:\/\/doi.org\/10.1080\/01621459.2016.1260466.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"3088_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol. 2019;188(1):250\u20137. https:\/\/doi.org\/10.1093\/aje\/kwy201.","journal-title":"Am J Epidemiol"},{"issue":"23","key":"3088_CR19","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1001\/jama.2020.7819","volume":"323","author":"LE Thomas","year":"2020","unstructured":"Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323(23):2417\u20138. https:\/\/doi.org\/10.1001\/jama.2020.7819.","journal-title":"JAMA"},{"issue":"11","key":"3088_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care"},{"issue":"12","key":"3088_CR21","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/pds.1673","volume":"17","author":"PC Austin","year":"2008","unstructured":"Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202\u201317. https:\/\/doi.org\/10.1002\/pds.1673.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"3088_CR22","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","volume":"39","author":"AS Ismaila","year":"2022","unstructured":"Ismaila AS, Haeussler K, Czira A, et al. Fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis. Adv Ther. 2022;39(9):3957\u201378. https:\/\/doi.org\/10.1007\/s12325-022-02231-0.","journal-title":"Adv Ther"},{"issue":"4","key":"3088_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3111\/13696998.2011.594123","volume":"14","author":"AP Yu","year":"2011","unstructured":"Yu AP, Guerin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486\u201396. https:\/\/doi.org\/10.3111\/13696998.2011.594123.","journal-title":"J Med Econ"},{"issue":"5","key":"3088_CR24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11606-008-0544-x","volume":"23","author":"F Pan","year":"2008","unstructured":"Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611\u20134. https:\/\/doi.org\/10.1007\/s11606-008-0544-x.","journal-title":"J Gen Intern Med"},{"key":"3088_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/copd.s184653","volume":"14","author":"M Bogart","year":"2019","unstructured":"Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343\u201352. https:\/\/doi.org\/10.2147\/copd.s184653.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3088_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12890-022-01892-5","volume":"22","author":"J O'Toole","year":"2022","unstructured":"O\u2019Toole J, Krishnan M, Riekert K, Eakin MN. Understanding barriers to and strategies for medication adherence in COPD: a qualitative study. BMC Pulm Med. 2022;22(1):98. https:\/\/doi.org\/10.1186\/s12890-022-01892-5.","journal-title":"BMC Pulm Med"},{"issue":"7","key":"3088_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s40266-023-01038-0","volume":"40","author":"MG Matera","year":"2023","unstructured":"Matera MG, Hanania NA, Maniscalco M, Cazzola M. Pharmacotherapies in older adults with COPD: challenges and opportunities. Drugs Aging. 2023;40(7):605\u201319. https:\/\/doi.org\/10.1007\/s40266-023-01038-0.","journal-title":"Drugs Aging"},{"issue":"11","key":"3088_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/thx.2009.113662","volume":"64","author":"J Vestbo","year":"2009","unstructured":"Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939\u201343. https:\/\/doi.org\/10.1136\/thx.2009.113662.","journal-title":"Thorax"},{"issue":"2","key":"3088_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.5603\/piap.2014.0015","volume":"82","author":"D Wi\u015bniewski","year":"2014","unstructured":"Wi\u015bniewski D, Porzezi\u0144ska M, Grucha\u0142a-Niedoszytko M, Niedoszytko M, S\u0142omi\u0144ski JM, Jassem E. Factors influencing adherence to treatment in COPD patients and its relationship with disease exacerbations. Pneumonol Alergol Pol. 2014;82(2):96\u2013104. https:\/\/doi.org\/10.5603\/piap.2014.0015.","journal-title":"Pneumonol Alergol Pol"},{"issue":"1","key":"3088_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1465-9921-15-66","volume":"15","author":"JF van Boven","year":"2014","unstructured":"van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. Respir Res. 2014;15(1):66. https:\/\/doi.org\/10.1186\/1465-9921-15-66.","journal-title":"Respir Res"},{"issue":"9","key":"3088_CR31","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s12325-019-01015-3","volume":"36","author":"F Maltais","year":"2019","unstructured":"Maltais F, Ferguson GT, Feldman GJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate\/formoterol fumarate metered dose inhaler relative to umeclidinium\/vilanterol dry powder inhaler in COPD. Adv Ther. 2019;36(9):2434\u201349. https:\/\/doi.org\/10.1007\/s12325-019-01015-3.","journal-title":"Adv Ther"},{"issue":"10","key":"3088_CR32","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/03007995.2023.2247969","volume":"39","author":"D Stolz","year":"2023","unstructured":"Stolz D, Hermansson E, Ouwens M, et al. Mortality risk reduction with budesonide\/glycopyrrolate\/formoterol fumarate versus fluticasone furoate\/umeclidinium\/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT. Curr Med Res Opin. 2023;39(10):1395\u2013405. https:\/\/doi.org\/10.1080\/03007995.2023.2247969.","journal-title":"Curr Med Res Opin"},{"key":"3088_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.105857","volume":"161","author":"DA Mahler","year":"2020","unstructured":"Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med. 2020;161:105857. https:\/\/doi.org\/10.1016\/j.rmed.2019.105857.","journal-title":"Respir Med"},{"key":"3088_CR34","unstructured":"Elixhauser A, Steiner C, Kruzikas D. Healthcare Cost and Utilization Project (HCUP). Elixhauser Comorbidity Software. 2015."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03088-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03088-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03088-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:54:07Z","timestamp":1738407247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03088-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3088"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03088-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Mannino is a consultant for AstraZeneca, the COPD Foundation, Genentech, GSK, Regeneron, and Up-to-Date. David Mannino is also an expert witness on behalf of people suing the tobacco and vaping industries. Stephen Weng, Sergio Forero-Schwanhaeuser, Chris H Compton, Stephen G Noorduyn, and Rosirene Paczkowski are employees of GSK and\/or hold financial equities in GSK. Stephen G Noorduyn is also a PhD candidate at McMaster University. Guillaume Germain, Julien Boudreau, Anabelle Tardif-Samson, Fran\u00e7ois Lalibert\u00e9, and Patrick Gravelle are employees of Groupe d\u2019analyse, which received funding from GSK to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study complied with all applicable laws regarding patient privacy, as described in the Declaration of Helsinki. No direct patient contact or primary collection of individual human patient data has occurred in this study. This study used existing, fully de-identified data that complied with the requirements of the Health Insurance Portability and Accountability Act and the patient(s) cannot be identified, directly or through identifiers. Study results were in tabular form and aggregate analyses that omit patient identification; therefore, informed consent, ethics committee or Institutional Review Board approval were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}